Real Estate, Healthcare Jun 23, 2021 06:00 PM (GMT+8) · EqualOcean
According to the official wechat "China Yaowen" released by the State Drug Administration, the class 1 innovative drug amitenofovir tablet (trade name: hengmu) has recently been approved to go on the market through the priority review and approval procedure. It is an innovative drug independently developed by China with independent intellectual property rights and can be used for the treatment of adult patients with chronic hepatitis B.